Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

Home Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

/ Publications

Share the Post

About the Author

Related Posts

Read More
Scott Giacobello, CPA
Read More
Neil Desai, PhD
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Read More
Behzad Aghazadeh, PhD
Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa

Comments

Comments are closed.